Subscribe to RSS
DOI: 10.1055/s-0031-1273770
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York
Comparison of Efficacy of Pitavastatin and Colestimide in Japanese Patients with Diabetes Mellitus Complicated by Hyperlipidemia and Metabolic Syndrome
Publication History
received 20.01.2011
first decision 21.02.2011
accepted 28.02.2011
Publication Date:
06 April 2011 (online)

Abstract
The present study was undertaken to compare the efficacy of pitavastatin and colestimide in patients with diabetes mellitus complicated by hyperlipidemia and metabolic syndrome. 48 diabetic patients with metabolic syndrome were randomly assigned to a pitavastatin group or colestimide group. The clinical parameters, serum lipids, fasting (FPG) and postprandial plasma glucose(PPG), HOMA-IR, hemoglobin A1c(HbA1c), hs-CRP and urinary albumin were measured before/after 24-week administration. Treatment with pitavastatin reduced LDL-C and TG, while that with colestimide significantly reduced waist circumference, BMI, LDL-C, HbA1c, FPG, PPG, HOMA-R , hs-CRP and urinary albumin. Percent improvement in LDL-C was greater in the pitavastatin group than in the colestimide group. Colestimide appeared to be useful in the management of Japanese patients with diabetes mellitus complicated by metabolic syndrome, since it alleviates obesity and insulin resistance in addition to exhibiting lipid profile-improving effects, and can thus improve markers of atherosclerosis.
Key words
atherosclerosis - LDL-cholesterol (LDL-C) - high-sensitivity CRP (hs-CRP)
References
- 1
Alberti KG, Zimmet P, Shaw J.
The metabolic syndrome – a new worldwide definition.
Lancet.
2005;
366
1059-1062
MissingFormLabel
- 2
Ast M, Frishman WH.
Bile acid sequestrants.
J Clin Pharm.
1990;
30
99-106
MissingFormLabel
- 3
Devaraj S, Autret B, Jialal I.
Effect of Colesevelam Hydrochloride(WelChol) on Biomarkers of Inflammation in Patients
With Mild Hypercholesterolemia.
Am J Cardiol.
2006;
98
641-643
MissingFormLabel
- 4
Examination Committee for Metabolic Syndrome Diagnostic Criteria.
.
Japanese Metabolic Syndrome Diagnostic Criteria.
J Jpn Soc Intern Med.
2005;
94
(4)
794-809
MissingFormLabel
- 5
Handa N, Matsumoto M, Maeda H. et al .
Ultrasonic evaluation of early carotid atherosclerosis.
Stroke.
1990;
21
1567-1572
MissingFormLabel
- 6
Kajiyayama G, Tzazumz S, Yamashita G. et al .
Effect of MIC-196 on biliary lipids metabolism in patients with hypercholesterolemia.
Rinsho Iyaku.
1996;
12
1349-1359
MissingFormLabel
- 7
Kawabata Y, Ikegami H, Fujisawa T. et al .
Bile-acid binding resin ameliorates glycemic control in patients with type 2 Diabetes.
Diabetes.
2006;
55
(supple 1)
120A
MissingFormLabel
- 8
Kobayashi M, Ikegami H, Fujisawa T. et al .
Prevention and treatment of obesity, insulin resistance and diabetes by bile acid-binding
resin.
Diabetes.
2007;
56
239-247
MissingFormLabel
- 9
Levy RI, Brensike JF, Epstein SE. et al .
The influence of changes in lipid values induced by cholestyramine and diet on progression
of coronary artery disease: results of the NHLBI Type II Coronary Intervention study.
Circulation.
1984;
69
325-337
MissingFormLabel
- 10
Lipid Research Clinics Program.
.
The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction
in incidence of coronary heart disease.
JAMA.
1984;
251
351-364
MissingFormLabel
- 11
Nakata M, Nagasaka S, Kusaka L. et al .
Effects of statins on the adipocyte maturation and expression of glucose transporter
4)SCL2A4): implications in glycaemic control.
Diabetologia.
2006;
49
1881-1892
MissingFormLabel
- 12
Naveed S, David P, Heather MM. et al .
Statins and risk of incident diabetes: a collaborative meta-analysis of randomized
statin trials.
Lancet.
2010;
375
735-742
MissingFormLabel
- 13
Osaki F, Ikeda Y, Hiroshue T. et al .
Effects of stains on glucose metabolism.
Japanese Journal of Clinical & Experimental Medicine.
2005;
82
359-363
MissingFormLabel
- 14
Research and Study Committee for Diagnostic Criteria of Diabetes Mellitus.
.
Report of the Committee of Japan Diabetes Society on the Classification and Diagnostic
Criteria of Diabetes Mellitus.
Journal of the Japan Diabetic Society.
2010;
53
450-467
MissingFormLabel
- 15
Ridker PM.
Clinical application of C-reactive protein for cardiovascular disease detection and
prevention.
Circulation.
2003;
107
363-369
MissingFormLabel
- 16
Sabatine MS, Wiviott SD, Morrow DA. et al .
High-dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22
substudy.
Circulation.
2004;
110
(Suppl III)
III–834. (Abstract)
MissingFormLabel
- 17
Sever PS, Poulter NR, Dahlôf B. et al .
For the ASCOT Investigators: Reduction in Cardiovascular Events With Atorvastatin
in 2 532 Patients With Type 2 Diabetes.
Diabetes Care.
2005;
28
(5)
1151
MissingFormLabel
- 18
Stayrook KR, Bramlett KS, Savkur RS. et al .
Regulation of carbohydrate metabolism by the farnesoid x receptor.
Endocrinology.
2005;
146
984-991
MissingFormLabel
- 19
Suzuki T, Obe K, Futami S. et al .
Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and
hypercholesterolemia: a case-control study comparing colestimide with acarbose.
Nippon Med Sch.
2006;
73
277-284
MissingFormLabel
- 20
Takebayashi K, Suetsugu M, Matsumoto S. et al .
Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte
chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia.
South Med J.
2009;
102
361-368
MissingFormLabel
- 21
Urizar NL, Liverman AB, Dodds DT. et al .
Anatural product that lowers cholesterol as an antagonist ligand for FXR.
Science.
2002;
296
1703-1706
MissingFormLabel
- 22
Watanabe M, Houten SM, Mataki C. et al .
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation.
Nature.
2006;
439
484-489
MissingFormLabel
- 23
Yamakawa T, Takano T, Utsunomiya H. et al .
Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with
hypercholesterolemia.
Endocr J.
2007;
54
(1)
53-58
MissingFormLabel
Correspondence
Prof. M. ItohMD, PhD
Division of Endocrinology and
Metabolism
Department of Internal
Medicine
Fujita Health University
School of Medicine
Toyoake Aichi 470–1192
Japan
Phone: +81/562/93 9242
Fax: +81/562/95 1879
Email: endolabo@fujita-hu.ac.jp